Hugh Cripps, MD
Family Medicine · Smithville, TNNPI 1255323382
Payments from drug & device makers
Across 280 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$893
- AbbVie$412
- AstraZeneca$341
- Boehringer Ingelheim$335
- Amgen$307
- Johnson & Johnson$307
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,76798%
- Education$822%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 55 | $893 |
| AbbVie | 27 | $412 |
| AstraZeneca | 18 | $341 |
| Boehringer Ingelheim | 18 | $335 |
| Amgen | 19 | $307 |
| Johnson & Johnson | 20 | $307 |
| Lilly USA, LLC | 17 | $262 |
| GSK | 16 | $244 |
| Astellas Pharma US Inc | 12 | $212 |
| Otsuka America Pharmaceutical, Inc. | 7 | $178 |
| Merck | 8 | $163 |
| Bayer | 6 | $117 |
| Pfizer | 5 | $100 |
| Exact Sciences | 5 | $96 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $69 |
| Sumitomo Pharma America, Inc. | 3 | $67 |
| Biogen | 1 | $67 |
| Corcept Therapeutics | 4 | $67 |
| Nestle Healthcare Nutrition Inc. | 3 | $65 |
| Phadia US Inc. | 4 | $55 |
| Collegium Pharmaceutical, Inc. | 1 | $46 |
| Novartis | 3 | $45 |
| GRT US Holding, Inc. | 1 | $44 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Seqirus USA Inc | 2 | $39 |
| Cipher Pharmaceuticals US LLC | 1 | $33 |
| Sanofi Pasteur Inc. | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Phathom Pharmaceuticals, Inc. | 4 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Tempus AI, Inc | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Biocryst Pharmaceuticals, Inc. | 1 | $16 |
| Almatica Pharma LLC | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $13 |
How this compares
$4,849 in reported general payments places this provider in the 80th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 187 | $166,362 |
| EliquisApixaban | 117 | $98,777 |
| OzempicSemaglutide | 83 | $96,807 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 93 | $73,222 |
| XareltoRivaroxaban | 98 | $73,066 |
| MounjaroTirzepatide | 50 | $59,595 |
| KerendiaFinerenone | 40 | $35,151 |
| MyrbetriqMirabegron | 56 | $28,902 |
| FarxigaDapagliflozin Propanediol | 47 | $28,808 |
| VraylarCariprazine Hcl | 23 | $25,605 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $17,175 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 13 | $12,068 |
| Pravastatin Sodium | 333 | $8,858 |
| Emgality PenGalcanezumab-Gnlm | 12 | $7,747 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $7,712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $335 | $171,214198 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $893 | $108,87596 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $244 | $100,343146 claims |
| PfizerEliquis | $100 | $98,777117 claims |
| Johnson & JohnsonXarelto | $307 | $73,06698 claims |
| Lilly USA, LLCMounjaro, Humalog Mix 75-25 | $262 | $63,10962 claims |
| BayerKerendia | $117 | $35,15140 claims |
| Astellas Pharma US IncMyrbetriq | $212 | $28,90256 claims |
| AstraZenecaFarxiga | $341 | $28,80847 claims |
| AbbVieVraylar | $412 | $25,60523 claims |
| MerckJanuvia | $163 | $4,92111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Smithville
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.